Advances, Challenges, and Future Directions in Inactivated Vaccine Technology
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 18
Special Issue Editors
Interests: tropical diseases and infections; pre-clinical vaccine development and testing; clinical vaccine trials
Interests: virus inactivated vaccines; microbiology; infectious diseases
Special Issue Information
Dear Colleagues,
Whole-pathogen inactivated vaccines have served as cornerstones of immunization programs for decades, yet technological advances continue to enhance their development and efficacy. This Special Issue examines cutting-edge innovations in inactivated vaccine technology, from novel inactivation methods and adjuvant systems to improved manufacturing processes and delivery platforms. We invite contributions addressing current challenges, including immunogenicity optimization, cold-chain requirements, and scalable production methods. Key topics encompass pathogen inactivation techniques, formulation strategies, stability enhancement, and next-generation platforms. This issue will explore regulatory considerations, quality control advances, and emerging applications of novel inactivation methods for complex pathogens. This comprehensive review aims to highlight scientific progress while identifying future research priorities to advance inactivated vaccine technology for global health applications. In this Special Issue, original research articles and reviews are welcome.
We look forward to hearing from you.
Prof. Dr. John Walton Sanders
Dr. Appavu K. Sundaram
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inactivated vaccines
- whole-cell vaccines
- pathogen inactivation
- adjuvant systems
- vaccine manufacturing
- immunogenicity enhancement
- vaccine stability
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
